{"id":"NCT04785326","sponsor":"Dong-A ST Co., Ltd.","briefTitle":"Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-28","primaryCompletion":"2022-02-10","completion":"2022-11-16","firstPosted":"2021-03-05","resultsPosted":"2024-01-18","lastUpdate":"2024-01-18"},"enrollment":598,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"DMB-3115","otherNames":[]},{"type":"DRUG","name":"Stelara","otherNames":[]}],"arms":[{"label":"DMB-3115","type":"EXPERIMENTAL"},{"label":"Stelara","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"• To Evaluate Efficacy of DMB-3115 in Comparison With Stelara","timeFrame":"Week 8 (For EMA) and 12 (For FDA)","effectByArm":[{"arm":"DMB-3115","deltaMin":77.5,"sd":2.595},{"arm":"Stelara","deltaMin":77.85,"sd":2.587}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":299},"commonTop":["Nasopharyngitis","COVID-19","Hypertension","Headache","Rhinitis"]}}